Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q2 2015 · 10-Q
Revenue$12.50K$12.50K— vs Q2 2014 Net Income-$146.93K-$146.93KN/M vs Q2 2014 EPS Diluted-$0.00-$0.00N/M vs Q2 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
-$137,294
N/M
Operating Cash Flowderived-$26,163N/M Free Cash Flowderived-$26,163N/M Margins · derivedGross margin100.0%
Operating margin-1098.4%
Net margin-1175.4%
ended Feb 29, 2016 · filed Apr 18, 2016 · 49 d after period end